HBV Watch - Issues Archive

 

HBV Watch™

Timely Information for Practicing Physicians


Monthly Issues

2003: March; April, May, June, July, August, September, October, November, December

 

2004: January, February, March, April, May, June, July, August, September, October, November, December

 

2005: January, February, March, April, May, June, July, August, September, October, November,

December

 

2006: January, February

Special Issues

2003 EASL Meeting Highlights

2003 Clinical Experts Panel Meeting Highlights

2004 AASLD Single Topic Meeting: New Directions in the Treatment of Hepatitis B

2004 EASL Meeting Highlights

2005 DDW Abstract Highlights

 

Topic Listing

REVIEWS

§         Antiviral prophylaxis of HBV carriers who receive immunosuppressive or cytotoxic chemotherapy

§         Antiviral therapy for prevention of perinatal HBV transmission

§         Chronic hepatitis B and kidney transplantation

§         Coinfection with hepatitis B virus and human immunodeficiency virus

§         HBsAg seroclearance: Outcomes in Chinese patients

§         Healthcare workers who are chronically infected with hepatitis B virus

§         Hepatitis B Vaccine Nonresponse

§         Hepatitis B virus (HBV) DNA levels and hepatocellular carcinoma

§         Noninvasive surrogate markers of hepatitis B virus (HBV) fibrosis

§         Occult HBV infection

§         Peginterferon Therapy for Chronic Hepatitis B

§         Prevention of HBV-related hepatocellular carcinoma

§         Prevention of HBV reinfection after liver transplantation

§         Serum HBV DNA level as a predictor of hepatocellular carcinoma

§         Topic review: noninvasive markers for assessment of hepatic fibrosis in chronic viral hepatitis 

§         Treatment of chronic hepatitis B in the human immunodeficiency virus (HIV)-infected patient

ACUTE SELF-LIMITED HBV INFECTION

§         Long term outcomes

ACUTE EXACERBATION OF HBV INFECTION

§         Population study of spontaneous HBeAg seroconversion

ADEFOVIR DIPIVOXIL

§         Adefovir dipivoxil therapy

§         Adefovir resistance: Association with viral rebound and hepatic decompensation

§         Development of an HBV polymerase mutation and clinical resistance

§         Genotype and viral response

§         Resistance surveillance

§         Results of treatment in lamivudine-resistant HBV infection

§         Treatment of HBeAg-negative chronic hepatitis B

§         Treatment of HBeAg-positive chronic hepatitis B

ANTIBODY TO HEPATITIS B SURFACE ANTIGEN (Anti-HBs)

§         Development of anti-HBs after liver transplantation

ANTIVIRAL THERAPY

§         Treatment of hepatitis B and C dual infection

BIOCHEMICAL MARKERS IN HBV PATIENTS

§         Prediction of histological lesions

CHILDHOOD CHRONIC HBV

•         Current therapeutic approaches

COINFECTION WITH HEPATITIS B AND HUMAN IMMUNODEFICIENCY VIRUS

§         Adefovir dipivoxil therapy for HBV/human immunodeficiency virus–1 (HIV-1) coinfection

§         Impact of HBV coinfection on outcomes of HIV patients

EPIDEMIOLOGY

§         Changes in a US community

§         Genotype and precore/core variants

§         Healthcare-related viral hepatitis transmission

HBeAg

§         Correlation with serum HBV DNA levels

§         Different mechanisms of HBeAg seroconversion

§         Meaning of HBeAg and significance of HBV levels

§         Long-term adefovir dipivoxil therapy in HBeAg negative patients

§         Long-term lamivudine therapy in HBeAg negative patients

§         Peginterferon alfa-2a vs lamivudine in HBeAg positive patients

HBsAg

§         Maternal HBsAg carrier status and pregnancy outcomes

HBV-Associated Polyarteritis Nodosa

§         Clinical characteristics and outcome

HBV GENOTYPE TESTING

§         Topic Review: Research tool or ready for “prime time”

HBV REACTIVATION

§         Breast cancer patients

§         HBV reactivation following lamivudine withdrawal in patients who completed cytotoxic chemotherapy

HBV VACCINATION

§         Hepatitis A and B vaccination: Adherence to guidelines

§         Lack of association with multiple sclerosis

§         Long-term follow-up of a randomized trial

§         Need for boosters and significance of HBsAg escape mutants

§         Newborn vaccination program in Taiwan

§         Protection after 15 years of follow-up

HBV REPLICATION

§         Covalently closed circular DNA (cccDNA)

HBV-RELATED ACUTE LIVER FAILURE

§         Virologic characteristics

hbv transmission

§         HBV DNA levels in serum, saliva, and urine

§         Laboratory-based screening of health care workers

HEPATOCELLULAR CARCINOMA

§         Association with HBV DNA level and genotype

§         Effectiveness of prophylactic lamivudine administration

§         HBV mode of transmission

§         HBV reactivation

§         Occult HBV as a possible risk factor for HCC

§         Prospective study of Taiwanese children with chronic HBV infection

§         Role of reproductive factors

§         Risk of HBV exacerbation after transcatheter arterial chemoembolization

§         Woodchuck hepatitis virus (WHV) animal model and N-myc rearrangements

IMMUNOPROPHYLAXIS

§         Long-term results following liver transplantation

Interferon Therapy

§         A study of individualized therapy

§         Impact on liver fibrosis progression

§         Long-term follow-up

§         Long-term suppression

§         Peginterferon alfa-2b alone or with lamivudine in patients with HBeAg-positive chronic hepatitis B

§         Staggered regimen of peginterferon alfa-2b and lamivudine in patients with HBeAg-positive chronic hepatitis B

Lamivudine therapy

§         Compassionate use

§         Determinants for sustained response

§         Durability of response

§         Early therapy for HBV patients undergoing chemotherapy is superior

§         Extended treatment following seroconversion

§         In hepatic decompensation

§         Histological outcomes

§         LAM-containing therapy for IFN nonresponders

§         LAM vs. LAM + hepatitis B immune globulin (HBIg) to prevent post-transplant HBV recurrence

§         Treatment of patients with advanced liver disease

§         Tenofovir disoproxil treatment

§         Long-term follow-up of peginterferon and lamivudine combination therapy

§         Long-term safety

§         Long-term treatment enhances durability of HBeAg loss

§         Results of 2 years of treatment in patients with HBeAg-negative HBV infection

§         Transient restoration of antiviral T-cell responses

§         Treatment of acute, severe hepatitis B

§         Treatment of children

LAMIVUDINE RESISTANT hbv